The optimal management of calcium and phosphate metabolism regulation in chronic kidney disease (CKD) is important in preventing fracture risk and vascular calcification and thus morbidity and mortality, global and vascular. Kidney transplant in a CKD context, usually with a pre-existing underlying renal osteodystrophy, malnutrition, chronic inflammation, hypogonadism and immunosuppression protocols still often made up of high-dose corticosteroid therapy, are all theoretical factors of post-transplantation bone disease. For other solid organ transplants, even though there is generally no underlying renal osteodystrophy before the transplant, the proportion of osteoporotic patients at the time of transplant is substantial. The bone risk in the immediate post-transplant period is notable. Patients' follow-up is based on biological, radiological and histological tools. Bone densitometry (DXA) is used to measure bone mass. However, recent international recommendations do not consider DXA as a valid tool to assess bone health in CKD patients. Moreover, it is less informative than peripheral quantitative tomography resolution (HR-pQCT). This latest technique, available in Lyon and Saint-Etienne, is more precise, allowing a three-dimensional study of the trabecular microarchitecture and compartmental volumetric bone density (total, cortical, trabecular), while similar to DXA in terms of radiation (less than 5 μSv). The prevention of cardiovascular risk factors is also part of the daily care of patients with a regular cardiac monitoring (heart ultrasound) and vascular (blood pressure, Doppler of the supra-aortic trunks). TRANSOS study aims to evaluate in a prospective cohort (longitudinal follow-up of 6 months), the bone status in patients receiving solid organ transplantation in the University Hospitals of Lyon and Saint-Etienne, using DXA and HR-pQCT (at baseline and month 6), in combination with classical biological and cardiovascular monitoring. Transplantation is an important activity in these two hospitals and this protocol provides the same bone follow-up for all solid organ transplants, with a reliable, efficient, non-invasive and low-dose radiation tool. The primary objective of TRANSOS study is to evaluate changes in tibial cortical density between the baseline and the 6th month post-transplant measured by HR-pQCT.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
137
Bone evaluation in transplant patients will be performed by HR-pQCT at baseline (either within 6 months before surgery or within 15 days following surgery) and 6 months post-intervention in order to assess its evolution.
Hôpital Femme Mère Enfant
Bron, France
Hopital Edouard Herriot
Lyon, France
CHU Saint Etienne
Saint-Etienne, France
Tibial cortical density measured by HR-pQCT
Time frame: at 6 months
trabecular bone area measured by HR-pQCT
Time frame: at 6 months
total bone area measured by HR-pQCT
Time frame: at 6 months
trabecular number measured by HR-pQCT
Time frame: at 6 months
trabecular thickness measured by HR-pQCT
Time frame: at 6 months
trabecular separation measured by HR-pQCT
Time frame: at 6 months
cortical perimeter measured by HR-pQCT
Time frame: at 6 months
Evaluation of bone markers by measuring calcium
Time frame: at 6 months
Evaluation of bone markers by measuring phosphate
Time frame: at 6 months
Evaluation of bone markers by measuring alkaline reserve
Time frame: at 6 months
Evaluation of bone markers by measuring PTH
Time frame: at 6 months
Evaluation of bone markers by measuring 25OHD3
Time frame: at 6 months
Evaluation of bone markers by measuring 1-25 OHD3
Time frame: at 6 months
Evaluation of bone markers by measuring FGF23
Time frame: at 6 months
Evaluation of bone markers by measuring CTX
Time frame: at 6 months
Evaluation of bone markers by measuring total alkaline phosphatase
Time frame: at 6 months
Evaluation of bone markers by measuring bone alkaline phosphatase
Time frame: at 6 months
Evaluation of bone markers by measuring osteocalcin
Time frame: at 6 months
Bone mineral density assessed by DXA
Time frame: at 6 months
Fractures onset assessed by DXA
Time frame: at 6 months
Cardiovascular events (death from cardiovascular cause, heart attack, stroke)
Time frame: at 6 months
PTH
For kidney transplant only
Time frame: Baseline
1-25 OHD
For kidney transplant only
Time frame: Baseline
FGF 23
For kidney transplant only
Time frame: Baseline
calcium
For kidney transplant only
Time frame: Baseline
phosphate
For kidney transplant only
Time frame: Baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.